|
Market Closed -
Nasdaq
21:00:00 16/10/2026 BST
|
5-day change | 1st Jan Change | ||
| 157.14 USD | -2.87% |
|
-6.66% | -13.96% |
| 10-14 | Axsome Shows Valuation Disconnect Ahead of Q3, RBC Says | MT |
| 10-08 | RBC Trims Price Target on Axsome Therapeutics to $295 From $297, Keeps Outperform Rating | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Biopharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 8.47B | - | ||||
| 1,116B | |||||
| 610B | |||||
| 501B | |||||
| 358B | |||||
| 366B |
Select your edition
All financial news and data tailored to specific country editions
